Moderna rose 10.1% in pre-market trading. The stock remains in a volatile price discovery phase following the historic 177% single-day surge triggered by its mRNA cancer vaccine Phase III trial success.
NetEase shares rose 4.2% in morning trading. Goldman Sachs analyst Lincoln Kong maintained a Buy rating on NetEase and set a price target of $168.
Bloom Energy shares gained 3.5% in morning trading. The filing, signed by Pelosi on Aug. 21, showed purchases of 15,000 shares of Bloom Energy and 200 call options. The energy stock has emerged as a beneficiary of the AI-driven surge in demand for power.
Nebius shares rose 3.3% in morning trading after Goldman Sachs raised target price. Goldman Sachs raised its price target for Nebius to $328 from $286 and maintained a Buy rating.